Payment overview · 2025
General Payments
$18.85
1 reported records · 1 companies
Healthcare provider profile · identity verified
Kevin Harada, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HAVRE, MT · NPI 1760709661
Verified facts
What the public records show
CMS Open Payments records show Kevin Harada, M.D. received $18.85 in general payments during 2025 across 1 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 166 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
166 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 880 | 143 |
| Atorvastatin Calcium | Atorvastatin Calcium | 798 | 155 |
| Lisinopril | Lisinopril | 640 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 546 | 129 |
| Tamsulosin Hcl | Tamsulosin Hcl | 495 | 105 |
| Omeprazole | Omeprazole | 482 | 79 |
| Furosemide | Furosemide | 436 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 428 | 104 |
| Gabapentin | Gabapentin | 388 | 65 |
| Losartan Potassium | Losartan Potassium | 379 | 97 |
| Trazodone Hcl | Trazodone Hcl | 357 | 66 |
| Eliquis | Apixaban | 355 | 56 |
| Metformin Hcl | Metformin Hcl | 287 | 65 |
| Simvastatin | Simvastatin | 270 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 263 | 60 |
| Citalopram Hbr | Citalopram Hydrobromide | 242 | 35 |
| Potassium Chloride | Potassium Chloride | 232 | 54 |
| Warfarin Sodium | Warfarin Sodium | 231 | 24 |
| Famotidine | Famotidine | 217 | 25 |
| Benztropine Mesylate | Benztropine Mesylate | 213 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 204 | 26 |
| Allopurinol | Allopurinol | 193 | 41 |
| Propranolol Hcl | Propranolol Hcl | 183 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 47 |
| Carvedilol | Carvedilol | 176 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 170 | 44 |
| Jardiance | Empagliflozin | 166 | 22 |
| Lorazepam | Lorazepam | 159 | 25 |
| Clonazepam | Clonazepam | 155 | 18 |
| Ozempic | Semaglutide | 151 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 149 | 27 |
| Levetiracetam | Levetiracetam | 148 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 146 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 141 | 12 |
| Spironolactone | Spironolactone | 141 | 26 |
| Tramadol Hcl | Tramadol Hcl | 140 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 139 | 36 |
| Januvia | Sitagliptin Phosphate | 131 | 22 |
| Risperidone | Risperidone | 130 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 127 | 21 |
| Meloxicam | Meloxicam | 126 | 18 |
| Olanzapine | Olanzapine | 123 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 121 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 120 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 114 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 38 |
| Klor-Con M20 | Potassium Chloride | 111 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 27 |
| Finasteride | Finasteride | 95 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 82 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 81 | 24 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 81 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 79 | 16 |
| Xarelto | Rivaroxaban | 78 | 15 |
| Metformin Hcl Er | Metformin Hcl | 76 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 76 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 12 |
| Novolog Flexpen | Insulin Aspart | 75 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 69 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 69 | suppressed |
| Hydrocortisone | Hydrocortisone | 67 | suppressed |
| Ibuprofen | Ibuprofen | 64 | 16 |
| Aripiprazole | Aripiprazole | 62 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 62 | 12 |
| Lamotrigine | Lamotrigine | 62 | suppressed |
| Myrbetriq | Mirabegron | 62 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 20 |
| Pregabalin | Pregabalin | 61 | 11 |
| Celecoxib | Celecoxib | 59 | 17 |
| Montelukast Sodium | Montelukast Sodium | 57 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 19 |
| Lovastatin | Lovastatin | 55 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 13 |
| Farxiga | Dapagliflozin Propanediol | 54 | suppressed |
| Ezetimibe | Ezetimibe | 52 | suppressed |
| Torsemide | Torsemide | 52 | 12 |
| Mirtazapine | Mirtazapine | 50 | suppressed |
| Nystatin | Nystatin | 50 | 20 |
| Glipizide | Glipizide | 49 | 15 |
| Victoza 2-Pak | Liraglutide | 49 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 13 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 48 | 47 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | suppressed |
| Trulicity | Dulaglutide | 48 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 41 |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | 12 |
| Bupropion Xl | Bupropion Hcl | 46 | 12 |
| Divalproex Sodium | Divalproex Sodium | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Chlorthalidone | Chlorthalidone | 43 | 11 |
| Haloperidol | Haloperidol | 43 | suppressed |
| Prednisone | Prednisone | 42 | 34 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 34 | suppressed |
| Naproxen | Naproxen | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 19 |
| Prazosin Hcl | Prazosin Hcl | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 31 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 31 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Fentanyl | Fentanyl | 30 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 27 | suppressed |
| Constulose | Lactulose | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Sulfasalazine | Sulfasalazine | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Levofloxacin | Levofloxacin | 22 | 19 |
| Oxtellar Xr | Oxcarbazepine | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 11 |
| Topiramate | Topiramate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Scopolamine | Scopolamine | 20 | suppressed |
| Buprenorphine | Buprenorphine | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Klor-Con 10 | Potassium Chloride | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 18 |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Xifaxan | Rifaximin | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Austedo | Deutetrabenazine | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $18.85 · 1 records | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error